chemie.pr-1A-Network - Gästebücher Newsletter Quiz Umfragen Counter ...
Bei 1A-Network erhalten Sie alles für Ihre Homepage. Data Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120)
Data Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120)
25.04.2008 16:40:06
Boehringer Ingelheim: Ingelheim, Germany (ots/PRNewswire) - - For non-US Healthcare Media - Abstract # 163O. von Pawel. Proffered Papers 6 - Advanced NSCLC - Latest Phase II Data for Boehringer Ingelheim's New Cancer Drug in Development Presented Monotherapy treatment with the triple angiokinase inhibitor(1) BIBF 1120 (planned tradename VARGATEF(TM)) offers promising efficacy and is well tolerated in patients with advanced, relapsed non-small ...
Lesen Sie hier weiter... |
Drucken |
PDF
Ähnliche Artikel
- Erste Taxan-basierte Anthrazyklin-freie Chemotherapie in Kombination mit Herceptin (TCH) für Patientinnen mit HER2-positivem frühem Brustkrebs erhält FDA-Zulassung
- New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients
- New Data Confirms Avastin (R) as the Only Biologic to Demonstrate Overall Survival When Used First-Line in Metastatic Colorectal Cancer Patients With K-RAS (Wild-Type) Gene Status
- First Pivotal Trials Begin for Boehringer Ingelheim's Novel Triple Angiokinase Inhibitor Vargatef(TM) (BIBF 1120)
- Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer
- Boehringer Ingelheim Broadens Oncology Pipeline With Promising New Data for Potentially First in Class Plk1 Inhibitor
- Industry Leaders Select Resverlogix's RVX-208 Among Top 10 Most Promising Drugs
- New Data Demonstrates Joint Damage is Inhibited With Wyeth's Biologic Enbrel(R) Plus Methotrexate in Patients With Early Active Rheumatoid Arthritis
- Patients With Pancreatic Cancer can Benefit From Avastin(R) Plus Tarceva(R)
- Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting
Presseportal: Boehringer Ingelheim
Data Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120) (1) BIBF 1120 (planned tradename VARGATEF(TM)) offers
Bionity.COM Newsletter
Data suggests promising overall survival and progression-free survival with VARGATEF (BIBF 1120) (TM)) offers promising efficacy and is well tolerated in
Presseportal.de - Boehringer Ingelheim
Pipeline With Promising New Data for Potentially Data Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120)
stock-channel.net - Das Finanzportal - Data Suggests Promising Overall ...
Data Suggests Promising Overall Survival and Progression-Free Survival With VARGATEF(TM) (BIBF 1120) (1) BIBF 1120 (planned tradename VARGATEF(TM)) offers